FDA device center's adverse event assessments get OIG critique
This article was originally published in The Gray Sheet
Executive Summary
The FDA device center does not systematically use adverse events to detect and address device safety concerns, according to an Oct. 23 report from the Health and Human Services Office of Inspector General. From an investigation of the center's adverse event databases and interviews with officials, OIG concludes that CDRH does not consistently document follow-up on adverse event reports, and staffers do not consistently read the reports in a timely manner after submission. The agency also does not decisively enforce reporting deadlines, in particular the five-day deadline for events that require action other than routine maintenance or service to prevent a public health issue. OIG recommends that FDA develop a better protocol for reviewing adverse events and enhance outreach to user facilities to prevent underreporting. FDA says it agrees with the recommendations
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.